Products
Ivicentamab Biosimilar Biparatopic Antibody (CD37) for Research
Cat No.: GMP-Bios-ab-673
Pre-Made Ivicentamab biosimilar, Whole mAb, Anti-CD37;CD37 Antibody: Anti-GP52-40/TSPAN26;GP52-40/TSPAN26 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-673-1mg | 1mg | |
| GMP-Bios-ab-673-10mg | 10mg | |
| GMP-Bios-ab-673-100mg | 100mg | |
| GMP-Bios-ab-673-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ivicentamab biosimilar, Whole mAb, Anti-CD37;CD37 Antibody: Anti-GP52-40/TSPAN26;GP52-40/TSPAN26 therapeutic antibody |
| INN Name | Ivicentamab |
| Target | CD37;CD37 |
| Format | Bispecific Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1;IgG1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2021 |
| Year Recommended | na |
| Companies | Genmab |
| Conditions Approved | na |
| Conditions Active | B cell Lymphoma |
| Conditions Discontinued | na |
| Development Tech | DuoBody |
About target - CD37
1. Protein Leukocyte antigen CD37
2. Gene CD37
3. Organism Homo sapiens (Human)
Function
Enzyme and pathway databases
PathwayCommons P11049
